Cardiovascular Events for a Long Time End of COVID 19 Infection — LONGCOVIDWP3  

Myocardial Disease Clinical Trial

Official title: LONGCOVID WP3 "Cardiovascular Events for a Long Time End of COVID 19 Infection "

Status Active, not recruiting

Clinical Trial Summary

In the follow-up of partecipants with Covid-19 infection, persistence of cardiovascular symptoms is common. Studies on the acute phase of Covid-19 infection have demonstrated a significant prevalence of acute myocardial damage (15-44%), and imaging studies have confirmed the presence of structural changes in the pericardium and myocardium several months after the acute phase. The aim of the project is to identify the prevalence and characteristics of long-term cardiovascular changes in Covid-19 infection.

Clinical Trial Description

The study is a continuation of the "CARDICoVRISK" registry project ("Cardiovascular risk and effects ancillary effects of cardiology drug therapy during n-CoV-19 infection"), which collected data on alterations cardiovascular changes during the acute phase and shortly after the acute phase.

The design of the current study is observational cross-sectional comparison with historical data. The study plans to enroll 240 patients hospitalized during the acute phase of COVID-19 infection. Enrollment of patients will be carried out in three separate centers. Enrolled patients will undergo a baseline assessment by history, objective examination, laboratory tests, ECG, 6-minute walking test and echocardiogram. ;

Related Conditions & MeSH terms

• Cardiomyopathies
• COVID-19
• Myocardial Disease

• NCT number: NCT05729152
• Study type: Observational [Patient Registry]
• Source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Status: Active, not recruiting
• Start date: September 6, 2022
• Completion date: May 26, 2023